CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin's disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 25 citations in OpenAlex.

1. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.British journal of haematology · 2014
   Trial
2. NFkB Pathway and Hodgkin Lymphoma.Biomedicines · 2022
   Review
3. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.Haematologica · 2016
   Review
4. New molecular targets for treatment of lymphoma.Current oncology reports · 2004
   Review

Corrections and comments

• Comment on
  CD40 expression in Hodgkin's disease.1994

Authors and funding

4 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as